 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
 |
 |
 |
 |

Online Early |
 |
 Current Issue Core Evidence
Vol. 2, No. 4
July, 2008
ISSN: 1555-1741 |
 |

Free Trial |
 |
Sample |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| Editorial |
|
Editor-in-Chief |
| |
 |
Paul Chrisp, PhD |
 |
Editor, North America |
| |
 |
Doris Peter, PhD |
|
Consultant Editor |
| |
 |
Stephen R. Chapman, PhD |
 |
International editorial board |
| |
 |
Darren M. Ashcroft, PhD, University of Manchester,
Manchester, UK |
| |
 |
Henry R. Black, MD, Rush University Medical Center,
Chicago, IL, USA |
| |
 |
G. Walter Canonica, MD, University of Genoa,
Genoa, Italy |
| |
 |
Joshua P. Cohen, PhD, Tufts Center for the Study
of Drug Development, Boston, MA, USA |
| |
 |
Sharon Conroy, BPharm, Derbyshire Children’s
Hospital, Derby, UK |
| |
 |
Sanford I. Finkel, MD, University of Chicago
Medical School, Chicago, IL, USA |
| |
 |
John A. Glaspy, MD, UCLA School of Medicine,
Los Angeles, CA, USA |
| |
 |
Abraham G. Hartzema, PharmD, University of Florida,
Gainesville, FL, USA |
| |
 |
Joel W. Hay, PhD, University of Southern California,
Los Angeles, CA, USA |
| |
 |
David M. Herrington, MD, Wake Forest University
School of Medicine, Winston-Salem, NC, USA |
| |
 |
Stephen T. Holgate, MD, Southampton General Hospital,
Southampton, UK |
| |
 |
Philip D. Home, DM, University of Newcastle upon
Tyne, Newcastle upon Tyne, UK |
| |
 |
Martin Knapp, PhD, London School of Economics
and Political Science, London, UK |
| |
 |
Andrew J. Krentz, MD, Southampton General Hospital,
Southampton, UK |
| |
 |
Paul C. Langley, PhD, University of Minnesota,
Minneapolis, MN, USA |
| |
 |
Peter G.M. Mol, PhD, University Medical Center
Groningen, Groningen, the Netherlands |
| |
 |
Robert P. Navarro, PharmD, Campbell Alliance,
Raleigh, NC, USA |
| |
 |
Donal J. O'Donoghue, MD, Hope Hospital, Manchester,
UK |
| |
 |
Olivier Rascol, MD, Toulouse University Hospital,
Toulouse, France |
| |
 |
Emilio J. Sanz, MD, University of La Laguna School
of Medicine, La Laguna, Tenerife, Spain |
| |
 |
David L. Scott, MD, King’s College Hospital,
London, UK |
| |
 |
Ya-Chen Tina Shih, PhD, University of Texas M.
D. Anderson Cancer Center, Houston, TX, USA |
| |
 |
Dominic A. Sica, MD, Virginia Commonwealth
University, Richmond, VA, USA |
| |
 |
Andy Stergachis, PhD, University of Washington,
Seattle, WA, USA |
| |
 |
Sean D. Sullivan, PhD, University of Washington,
Seattle, WA, USA |
| |
 |
Nicholas J. Talley, MD, Mayo Clinic, Rochester,
MN, USA |
| |
 |
Alan D. Tice, MD, John A. Burns School of Medicine,
Honolulu, HI, USA |
| |
 |
Tom Walley, MD, University of Liverpool, Liverpool,
UK |
| |
 |
Myron H. Weinberger, MD, Indiana University School
of Medicine, Indianapolis, IN, USA |
| |
 |
Alberto Zanchetti, MD, University of Milan, Milan,
Italy |
 |
Peer reviewed |
 |
The editorial process combines clearly
defined drug selection criteria, evidence-based medicine techniques,
and expert clinical opinion, written in a format based on formulary
requirements |
 |
Core Evidence is included
in EMBASE, EMNursing, Scopus, the Health Economic Evaluations
Database (HEED), and CINAHL. Indexing in all other major databases
is being applied for |
| |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|